In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan PLC

www.allergan.com

Latest From Allergan PLC

Keeping Track: Approvals For Polivy, Keytruda, FDA Applause For Biosimilars

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.

Biosimilars United States

Market-Changing Launches Expected In 2020

We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.

Market Intelligence Launches

Top US Court Refuses Restasis Review

The US Supreme Court has refused Allergan and the Saint Regis Mohawk Tribe’s request that it review a ‘blocking-patent’ doctrine applied by an appeals court in finding four Restasis patents invalid for obviousness.

Intellectual Property United States
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register